Abstract
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and by obstructive changes of the pulmonary vasculature including smooth muscle cell proliferation which leads to medial hypertrophy and subsequent luminal narrowing. Sildenafil, an orally active inhibitor of cGMP phosphodiesterase–type–5, exerts pulmonary vasodilator activity in PAH patients. We evaluated the effects of sildenafil on growth of cultured human pulmonary artery smooth muscle cells (PASMC). The results indicate that sildenafil reduced DNA synthesis stimulated by PDGF and dose dependently inhibited PASMC proliferation. These effects were paralleled by a progressive increase in cGMP content, followed by an accumulation of cAMP. The treatment with 8–bromo–cGMP or dibutyryl–cAMP mimicked all the effects of sildenafil. On the other hand, treatment of PASMC with inhibitors of cGMP–dependent protein kinase (PKG) or cAMP–dependent protein kinase (PKA) reversed the antiproliferative effect of sildenafil. In addition, sildenafil inhibited the phosphorylation of ERK, a converging point for several pathways leading to cell proliferation. This effect was partially reduced by PKG inhibition and completely abolished by PKA inhibition.
We conclude that sildenafil exerts an antiproliferative effect on human PASMC that is mediated by an interaction between the cGMP–PKG and the cAMP–PKA activated pathways, leading to inhibition of PDGF–mediated activation of the ERK.
Similar content being viewed by others
References
Bhatia S, Frantz RP, Severson CJ, Durst LA, McGoon MD (2003) Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78:1207–1213
Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type-5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47–52
Bradford MH (1976) A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Cook SJ, McCormick F (1993) Inhibition by cAMP of Ras-dependent activation of Raf. Science 262:1069–1072
Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274:13729–13732
Fukumoto S, Koyama H, Hosoi M, Yamakawa K, Tanaka S, Morii H, Nishizawa Y (1999) Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells: cGMP delays cell cycle transition through suppression of cyclin D1 and cyclin-dependent kinase 4 activation. Circ Res 85:985–991
Galiè N, Manes A, Branzi A (2003) Prostanoids for pulmonary arterial hypertension. Am J Respir Med 2:123–137
Galiè N, Manes A, Branzi A (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 61:227–237
Galiè N, Manes A, Uguccioni L, Serafini F, De Rosa M, Branzi A, Magnani B (1998) Primary pulmonary hypertension: insights into pathogenesis from epidemiology. Chest 114:184S–194S
Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522
Graves LM, Bornfeldt KE, Raines EW, Potts BC, Macdonald SG, Ross R, Krebs EG (1993) Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci USA 90:10300–10304
Gurujeyalakshmi G, Hollinger MA, Giri SN (1999) Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 276 :L311–L318
Jeffery TK, Wanstall JC (2001) Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 92:1–20
Koyama H, Bornfeldt KE, Fukumoto S, Nishizawa Y (2001) Molecular pathways of cyclic nucleotide-induced inhibition of arterial smooth muscle cell proliferation. J Cell Physiol 186:1–10
Michelakis Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL (2003) Long-Term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066–2069
Nelson PR, Yamamura S, Mureebe L, Itoh H, Kent KC (1998) Smooth muscle cell migration and proliferation are mediated by distinct phases of activation of the intracellular messenger mitogenactivated protein kinase. J Vasc Surg 27:117–125
Osinski MT, Rauch BH, Schror K (2001) Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59:1044–1050
Pietra GG, Edwards WD, Kay JM, Rich S, Kernis J, Schloo B, Ayres SM, Bergofsky EH, Brundage BH, Detre KM (1989) Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the NIH, Primary Pulmonary Hypertension Registry. Circulation 80:1198–1206
Pilz RB, Casteel DE (2003) Regulation of gene expression by cyclic GMP. Circ Res 93:1034–1046
Piper AS, Large WA (2004) Direct effect of Ca2+-calmodulin on cGMP-activated Ca2+-dependent Cl-channels in rat mesenteric artery myocytes. J Physiol 559:449–457
Polson JB, Strada SJ (1996) Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 36:403–427
Rabinovitch M (1998) Elastase and pathobiology of unexplained pulmonary hypertension. Chest 114:213S–224S
Rubin LJ (1997) Primary pulmonary hypertension. N Engl J Med 336 (2):111–117
Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280–291
Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. Journal of the American College of Cardiology 43:1149–1153
Satoh S, Makino N (2001) Intracellular mechanisms of cGMP-mediated regulation of myocardial contraction. Basic Res Cardiol 96:652–658
Simonneau G, Galie N, Rubin L, Langleben D, Seeger W, Dominighetti G, Gibbs S, Lebrec D, Speich S, Beghetti M, Rich S, Fishman A (2004) Epidemiology and Clinical Classification of Pulmonary Arterial Hypertension. J Am Coll Cardiol 43:5S–12S
Southgate K, Newby AC (1990) Seruminduced proliferation of rabbit aortic smooth muscle cells from the contractile state is inhibited by 8-Br-cAMP but not 8-Br-cGMP. Atherosclerosis 82:113–123
Stenmark KR, Mecham RP (1997) Cellular and molecular mechanisms of pulmonary vascular remodeling. Annu Rev Physiol 59:89–144
Suhasini M, Li H, Lohmann SM, Boss GR, Pilz RB (1998) Cyclic-GMP-dependent protein kinase inhibits the Ras/Mitogenactivated protein kinase pathway. Mol Cell Biol 18:6983–6994
Tantini B, Flamigni F, Pignatti C, Stefanelli C, Fattori M, Facchini A, Giordano E, Clo’ C, Caldarera CM (2001) Polyamines, NO and cGMP mediate stimulation of DNA synthesis by tumor necrosis factor and lipopolysaccharide in chick embryo cardiomyocytes. Cardiovasc Res 49:408–416
Tantini B, Pignatti C, Fattori M, Flamigni F, Stefanelli C, Giordano E, Menegazzi M, Clô C, Caldarera CM (2000) NF-kappaB and ERK cooperate to stimulate DNA synthesis by inducing ornithine decarboxylase and nitric oxide synthase in cardiomyocytes treated with TNF and LPS. FEBS Lett 512:75–79
Wu J, Dent P, Jelinek T, Wolfman A, Weber MJ, Sturgill TW (1993) Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3’,5’-monophosphate. Science 262:1065–1069
Yu SM, Hung LM, Lin CC (1997) cGMPelevating agents suppress proliferation of vascular smooth muscle cells by inhibiting the activation of epidermal growth factor signaling pathway. Circulation 95:1269–1277
Zhang S, Remillard CV, Fantozzi I, Yuan JX (2004) ATP-induced mitogenesis is mediated by CREB-enhanced TRPC4 expression and activity in human pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol Jun 30 (in press)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tantini, B., Manes, A., Fiumana, E. et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100, 131–138 (2005). https://doi.org/10.1007/s00395-004-0504-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00395-004-0504-5